Quince Therapeutics (NASDAQ:QNCX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Quince Therapeutics (NASDAQ:QNCX) issued its earnings results on Monday. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09), Zacks reports. The company had revenue of $0.17 million for the quarter.

Quince Therapeutics Trading Up 1.4 %

Shares of QNCX stock opened at $1.40 on Tuesday. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $1.49 and its two-hundred day moving average is $1.44. The company has a market capitalization of $61.60 million, a P/E ratio of -1.13 and a beta of 0.71.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on QNCX. Oppenheimer initiated coverage on Quince Therapeutics in a research note on Monday. They set an “outperform” rating and a $10.00 target price for the company. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Quince Therapeutics in a report on Wednesday, February 5th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Quince Therapeutics has a consensus rating of “Buy” and an average target price of $9.60.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.